ESREG, S.A. DE C.V. Estrategias y Soluciones Regulatorias Globales’ Post

Dose escalation is ongoing in the TNG348, a novel inhibitor of USP1 (ubiquitin-specific protease 1), phase 1/2 clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of TNG348 as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2 mutant and other HRD+ (homologous recombination deficient) cancers. The first patient dosed was announced in January 2024. Chemenu has been working to develop more compounds for drug discovery. Here come the building blocks we can provide: https://lnkd.in/dCZTey7t #TNG348 #USP1 #Olaparib #PARP #BRCA1/2 #HRD+ #Chemenu #buildingblocks

#CAR-T can cure Lupus, China’s drug company achieves significant improvement Recently, according to the official website of Center for Drug Evaluation, #e-cspc's CAR-T product, #SYS6020 Cell Injection, has been approved for clinical trials and is intended for the treatment of refractory active systemic lupus erythematosus (SLE). SYS6020 Cell Injection targets the #BCMA antigen and is expected to provide a new treatment option for #SLE patients with a lower cost. SYS6020 is also the first cell therapy product in the pipeline of the e-cspc. In the future, can CAR-T cure Lupus or not depends on more clinical data. We expect these clinical experiment to get good outcome, promoting CAR-T to become more safe, efficient and usable therapy for SLE patient.

OA therapeutics development should be focusing on clinical phenotypes, molecular endotypes, and theratypes. Understanding these elements is crucial for targeted treatment strategies, nicely discussed in this perspective by Ali Mobasheri and Loeser Richard. https://lnkd.in/gFHi5hua #osteoarthritis #DMOAD

AltPep CEO, Valerie Daggett presented at the 12th Annual Alzheimer’s and Parkinson’s Drug Development Summit today. Her talk, titled “Diagnostics and Therapeutics for Selective Targeting of Early Toxic Oligomers” overviewed AltPep’s SOBA assay and SOBIN therapeutic in Alzheimer’s disease, as well as the application of AltPep’s platform to other amyloid diseases including Parkinson’s disease. Click below to read her bio and learn more about the Summit. #innovation #AlzheimersDisease #ParkinsonsDisease #Research

Although JJP-1212 is developed by JJP Biologics the scientific background around the CD89-IgA axis remains an highly unexplored field.

JJP Biologics's JJP-1212 is the first programme worldwide exploring the CD89-IgA axis in clinical stage. Results of ongoing cohorts are promising. Stay tuned! #jjpbiologics #jjp1212 #smartstrategy

Membrane proteins are at the forefront of drug discovery, shaping the effectiveness of medications. They play a pivotal role in various cellular processes and are linked to numerous human diseases. Did you know that over 60% of FDA-approved drugs target membrane proteins? Check out our website to learn more about our meticulously validated antibodies, targeting key membrane proteins like Claudin 18, c-MET, Androgen Receptor, and more. Learn how they contribute to the study and more precise targeting of challenging yet vital drug targets. Explore: https://ow.ly/V6IE50QpcMV #AntibodyOfTheMonth #MembraneProteins #DrugDiscovery

The Impact of #Spinraza on Spinal Muscular Atrophy (SMA) 🌟🧠 Spinraza, a pioneering drug developed by Ionis Pharmaceuticals, has revolutionized the treatment of Spinal Muscular Atrophy (SMA), a severe neuromuscular disorder. Dr. Frank Bennett’s work has demonstrated that Spinraza can not only stabilize but also improve symptoms in SMA patients. By addressing the underlying genetic defect responsible for SMA, Spinraza offers hope where traditional treatments fall short. Discover how this breakthrough has set new standards in drug development and patient care for rare diseases. https://lnkd.in/gzD5g5_Z

Imatinib: A wondrous invention in the world of medicine 👉#Imatinib, a revolutionary pharmaceutical, has not just provided the medical industry with a new kind of success, but it has also sparked a wave of hope and inspiration. 👉 Known as #Gleevec or Glivec, Imatinib has led the charge against chronic myeloid leukaemia, ushering in a new era in cancer treatment. 👉#Imatinib manufacturer, a highly active medicine, doesn't just target proteins in cancer cells. It disrupts their growth. 👉 This powerful action gives hope in the fight against cancer, intruding on the development of some cancer cells and offering a promising future for cancer treatment. 💊Imatinib, a game-changer medicine, reshaped the lives of ample survivors who were suffering from foetal diseases like chronic myeloid leukaemia. 👉Read this entire blog about Imatinib: A wondrous invention in medicine. 👇👇 https://lnkd.in/giCzqGDk #Imatinib #Cancertreatment #Medicine #Gleevec

We're excited to introduce our latest service, the Cardiomyocyte Contraction Assay. Here's what our service offers: ✅ Drug Screening: Evaluate pharmacological compounds' effects on cardiomyocyte function, facilitating rapid screening of potential therapeutics for cardiovascular diseases. ✅ Mechanistic Insights: Uncover the underlying molecular mechanisms of drug candidates by studying their impact on cardiomyocyte contractility, providing critical insights into their mode of action. ✅ Safety Assessment: Assess the cardiotoxic effects of drugs and environmental toxins early in the drug development process, ensuring the safety and efficacy of your compounds. ✅ Flexibility: Our Cardiomyocyte Contraction Assay is available for both Rat Primary Cardiomyocytes and hiPSC-CMs, providing flexibility and adaptability to suit your research needs. #cardiomyocytes #safetypharmacology #drugdiscovery #contraction